These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 38990642)
1. Edoxaban enfolded beta-1,4-poly-d-glucosamine nanoparticles for targeting eponym Stuart-Prower factor for treatment of venous thrombosis. Pazhani P; Dharmian JP; Arumugam S; Pazhani P; Medapati VVP J Drug Target; 2024 Nov; 32(9):1125-1138. PubMed ID: 38990642 [TBL] [Abstract][Full Text] [Related]
2. Arg-Specific serine Protease-Targeted edoxaban tosylate monohydrate-Poly (lactic-co-glycolic acid) Nanoparticles: Investigating Stuart-Prower factor targeting and intestinal distribution through Ex-Vivo fluorescent visualization. Pazhani P; Prakash Dharmian J; Arumugam S; Pazhani P; Vara Prasad Medapati V Eur J Pharm Biopharm; 2024 Oct; 203():114459. PubMed ID: 39168255 [TBL] [Abstract][Full Text] [Related]
3. Alginate coated chitosan core shell nanoparticles for oral delivery of enoxaparin: in vitro and in vivo assessment. Bagre AP; Jain K; Jain NK Int J Pharm; 2013 Nov; 456(1):31-40. PubMed ID: 23994363 [TBL] [Abstract][Full Text] [Related]
4. Formulation and biopharmaceutical evaluation of risperidone-loaded chitosan nanoparticles for intranasal delivery. Rukmangathen R; Yallamalli IM; Yalavarthi PR Drug Dev Ind Pharm; 2019 Aug; 45(8):1342-1350. PubMed ID: 31094571 [No Abstract] [Full Text] [Related]
5. Chitosan-TPP nanoparticles stabilized by poloxamer for controlling the release and enhancing the bioavailability of doxazosin mesylate: Aljaeid BM; El-Say KM; Hosny KM Drug Dev Ind Pharm; 2019 Jul; 45(7):1130-1139. PubMed ID: 30884977 [No Abstract] [Full Text] [Related]
6. Bio-fabrication and statistical optimization of polysorbate 80 coated chitosan nanoparticles of tapentadol hydrochloride for central antinociceptive effect: in vitro-in vivo studies. Patil GB; Surana SJ Artif Cells Nanomed Biotechnol; 2017 May; 45(3):505-514. PubMed ID: 27017892 [TBL] [Abstract][Full Text] [Related]
7. Treatment of venous thrombosis with an oral direct factor Xa inhibitor edoxaban by single and multiple administrations in rats. Morishima Y; Kamisato C; Honda Y Eur J Pharmacol; 2014 Nov; 742():15-21. PubMed ID: 25179572 [TBL] [Abstract][Full Text] [Related]
8. Development and Optimization of Ciprofloxacin HCl-Loaded Chitosan Nanoparticles Using Box-Behnken Experimental Design. Soliman NM; Shakeel F; Haq N; Alanazi FK; Alshehri S; Bayomi M; Alenazi ASM; Alsarra IA Molecules; 2022 Jul; 27(14):. PubMed ID: 35889340 [TBL] [Abstract][Full Text] [Related]
9. Chitosan nanoconstructs for improved oral delivery of low molecular weight heparin: In vitro and in vivo evaluation. Paliwal R; Paliwal SR; Agrawal GP; Vyas SP Int J Pharm; 2012 Jan; 422(1-2):179-84. PubMed ID: 22079712 [TBL] [Abstract][Full Text] [Related]
10. Taurine loaded chitosan-pectin nanoparticle shows curative effect against acetic acid-induced colitis in rats. Ahmed O; Abdel-Halim M; Farid A; Elamir A Chem Biol Interact; 2022 Jan; 351():109715. PubMed ID: 34695389 [TBL] [Abstract][Full Text] [Related]
11. A study on the preparation of chitosan-tripolyphosphate nanoparticles and its entrapment mechanism for egg white derived peptides. Du Z; Liu J; Zhang T; Yu Y; Zhang Y; Zhai J; Huang H; Wei S; Ding L; Liu B Food Chem; 2019 Jul; 286():530-536. PubMed ID: 30827643 [TBL] [Abstract][Full Text] [Related]
12. Formulation of simvastatin chitosan nanoparticles for controlled delivery in bone regeneration: Optimization using Box-Behnken design, stability and in vivo study. Delan WK; Zakaria M; Elsaadany B; ElMeshad AN; Mamdouh W; Fares AR Int J Pharm; 2020 Mar; 577():119038. PubMed ID: 31953085 [TBL] [Abstract][Full Text] [Related]
13. Scalable ionic gelation synthesis of chitosan nanoparticles for drug delivery in static mixers. Dong Y; Ng WK; Shen S; Kim S; Tan RB Carbohydr Polym; 2013 May; 94(2):940-5. PubMed ID: 23544653 [TBL] [Abstract][Full Text] [Related]
14. Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays. Hillarp A; Strandberg K; Baghaei F; Fagerberg Blixter I; Gustafsson KM; Lindahl TL Scand J Clin Lab Invest; 2018; 78(7-8):575-583. PubMed ID: 30278787 [TBL] [Abstract][Full Text] [Related]
15. Methotrexate loading in chitosan nanoparticles at a novel pH: Response surface modeling, optimization and characterization. Hashad RA; Ishak RA; Geneidi AS; Mansour S Int J Biol Macromol; 2016 Oct; 91():630-9. PubMed ID: 27283234 [TBL] [Abstract][Full Text] [Related]
16. Formulation, development and optimization of raloxifene-loaded chitosan nanoparticles for treatment of osteoporosis. Saini D; Fazil M; Ali MM; Baboota S; Ali J Drug Deliv; 2015; 22(6):823-36. PubMed ID: 24725026 [TBL] [Abstract][Full Text] [Related]
17. Hybrid chitosan-lipid nanoparticles of green tea extract as natural anti-cellulite agent with superior Abosabaa SA; Arafa MG; ElMeshad AN Drug Deliv; 2021 Dec; 28(1):2160-2176. PubMed ID: 34623203 [TBL] [Abstract][Full Text] [Related]
18. Development, optimisation and evaluation of chitosan nanoparticles of alendronate against Alzheimer's disease in intracerebroventricular streptozotocin model for brain delivery. Zameer S; Ali J; Vohora D; Najmi AK; Akhtar M J Drug Target; 2021 Feb; 29(2):199-216. PubMed ID: 32876502 [TBL] [Abstract][Full Text] [Related]
19. Chitosan nanoparticles for intranasal delivery of olmesartan medoxomil: Pharmacokinetic and pharmacodynamic perspectives. Hassan RH; Gad HA; El-Din SB; Shaker DS; Ishak RAH Int J Pharm; 2022 Nov; 628():122278. PubMed ID: 36243325 [TBL] [Abstract][Full Text] [Related]
20. Mucopenetrating nanoparticles for enhancement of oral bioavailability of furosemide: In vitro and in vivo evaluation/sub-acute toxicity study. Radwan SE; Sokar MS; Abdelmonsif DA; El-Kamel AH Int J Pharm; 2017 Jun; 526(1-2):366-379. PubMed ID: 28487189 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]